Litcius/Paper detail

A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia

Andreas Meyer‐Lindenberg, Jacob Nielsen, Pedro Such, Ole Lemming, János Zámbori, R. Buller, Christoph von der Goltz

2022European Neuropsychopharmacology15 citationsDOI

Topics & Concepts

PlaceboDouble blindClinical endpointMedicineSchizophrenia (object-oriented programming)Randomized controlled trialPlacebo-controlled studyInternal medicineClinical trialGastroenterologyPsychiatryAlternative medicinePathologyPhosphodiesterase function and regulationBipolar Disorder and TreatmentAttention Deficit Hyperactivity Disorder
A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia | Litcius